India Biotech has applied for permission to test the vaccine experimentally in Bangladesh. The company has recently received emergency permission for their vaccine in India. The British news agency Reuters reported on Thursday (January 21st) quoting Bangladesh’s main medical research department.
No vaccine has been tested experimentally in Bangladesh yet. With India’s biotech approval, this will be the first trial of a vaccine in a country of more than 160 million people.
India Biotech has developed the vaccine with the Medical Research Council of India. This month, the country’s government approved the limited use of their vaccine without disclosing sufficient information about the third phase of the trial. Previous trials have shown that the vaccine is safe in the human body and is capable of building immunity.
Mahmud-uz-Jahan, director of the state-run Medical Research Council in Bangladesh, said, “We have received their proposal.” The policy-making committee will review the proposal. He declined to give details.
The Dhaka-based International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDRB) has applied to India Biotech for permission to conduct testing of the vaccine in Bangladesh. This information has been confirmed by a person directly involved in the matter who did not want to be named due to internal regulations.
ICDDRB declined to comment. A spokesman for Bharat Biotech was not immediately available for comment.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.